Soligenix, Inc. (SNGX)

Trade SNGX now with
5/16/2023 7:47:30 AM Soligenix Announces European Patent Grant For Use Of Dusquetide In Oral Mucositis
5/11/2023 7:32:40 AM Soligenix Updates On FDA Meeting Outcome Expected Next Month
5/5/2023 9:06:31 AM Soligenix Announces Pricing Of $8.5 Mln Public Offering
5/4/2023 7:44:09 AM Soligenix Announces Positive Results From Compatibility Study Of HyBryte In Treatment Of Cutaneous T-Cell Lymphoma
5/1/2023 7:37:07 AM Soligenix Reaches Deal With Silk Road For Rights To Topical Pentoxifylline Designed To Treat Behçet's Disease
4/5/2023 7:36:53 AM Soligenix Gets USAN Approval For Hypericin Sodium As Nonproprietary Name For Novel Active Ingredient In HyBryte, SGX302
4/3/2023 7:40:15 AM Soligenix Announces Scheduling Of Type A Meeting With FDA For HyBryte NDA In The Treatment Of Cutaneous T-Cell Lymphoma
2/14/2023 7:33:30 AM Soligenix Receives Refusal To File Letter From DA For HyBryte NDA In Treatment Of Cutaneous T-Cell Lymphoma
2/9/2023 7:40:36 AM Soligenix Intends To Effect Reverse Stock Split Of Stock At A Ratio Of 1 Post-split Share For Every 15 Pre-split Shares
12/20/2022 7:36:36 AM Soligenix Announces Publication Showing Positive Correlates Of Protection With RiVax In Non-Human Primate Survival
12/15/2022 7:43:36 AM Soligenix Submits NDA For HyBryte
12/15/2022 7:34:13 AM Soligenix Submits NDA To The FDA For HyBryte In The Treatment Of Cutaneous T-cell Lymphoma
11/10/2022 7:40:16 AM Soligenix Q3 Net Loss $3.3 Mln Or $0.08/shr Vs Loss $3.6 Mln Or $0.09/shr Prior Year